Put companies on watchlist
Limes Schlosskliniken AG
ISIN: DE000A0JDBC7
WKN: A0JDBC
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Limes Schlosskliniken AG · ISIN: DE000A0JDBC7 · EQS - adhoc news (20 News)
Country: Germany · Primary market: Germany · EQS NID: 1949233
18 July 2024 10:17AM

Positive business performance in the first half of 2024


EQS-Ad-hoc: Limes Schlosskliniken AG / Key word(s): Half Year Report/Preliminary Results
Limes Schlosskliniken AG: Positive business performance in the first half of 2024

18-Jul-2024 / 10:17 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


DGAP-Adhoc: Limes Schlosskliniken AG:

Positive business performance in the first half of 2024

  • Total revenue EUR 18.8m  + 33 %
     
  • Patient days 24,731  + 40 %
     
  • Gross earnings (EBITDA)  3,689 kEUR  + 28 %
     
  • Operating result (EBIT)  2,244 kEUR  + 25 %
     
  • Earnings before taxes 2,003 kEUR  + 24 %
     

Cologne, July 18, 2024: In the first half of 2024, the LIMES Group increased its total revenue by + 33 % to EUR 18.8 million. Overall, 40 % more patients were treated in the first six months, resulting in an increase in billed patient days to 24,731. The occupancy rate at the german LIMES Schlosskliniken developed positive. The performance of the PRC Zurich was temporarily weaker. However, we expect a significantly stronger second half-year there. The half-year figures include start-up costs for the two new locations amounting to 360 kEUR. Business development in the first half of the year was driven by the good operating performance of the existing LIMES clinics and the consolidation of Clinicum Alpinum.

The opening of the new LIMES Schlossklinik Abtsee is planned for the beginning of 2025. The handover of the second new clinic, LIMES Schlossklinik Bergisches Land, is scheduled for April 1, 2025. This will provide the LIMES Group with an additional 180 treatment places in 2025.

We are pleased that the LIMES brand stands for high-quality psychiatric services in the spectrum of stress-related illnesses, depression, trauma and personality disorders and is increasingly being well received on the market.

The detailed half-year report of LIMES Schlosskliniken will be published on September 3, 2024.

Brief profile: The LIMES Schlosskliniken Group operates high-quality private clinics for stress-related illnesses, mental and emotional disorders, such as depression, affective disorders and acute burnout conditions. The range of services is aimed at private patients, those entitled to subsidies and self-payers. The LIMES Schlosskliniken Group stands for the special approach of a relationship-oriented medicine in the treatment of people with mental illnesses. In addition to top medical quality, patients are offered a unique, protected and healing environment in which they can recover holistically. Further information is available at www.limes-schlosskliniken.de.

Your contact person:
LIMES Schlosskliniken AG, Petra Kaes, Investor Relations
Kaiser-Wilhelm-Ring 26, 50672 Cologne
Tel.: 0221 669 615 10, p.kaes@limes.care, www.limes-schlosskliniken.de

Language:  German
Company: LIMES Schlosskliniken AG, Kaiser-Wilhelm-Ring 26, 50672 Cologne, Germany
Phone:   49 221 669 615 10
Mail:  p.kaes@limes.care
Internet:  www.limes-schlosskliniken.de
ISIN:  DE000A0JDBC7
WKN:  AOJDBC
Stock exchange: Düsseldorf Open Market, Primary Market, XETRA

End of the message



End of Inside Information

18-Jul-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Limes Schlosskliniken AG
Kaiser-Wilhelm-Ring 26
50672 Köln
Germany
ISIN: DE000A0JDBC7
WKN: A0JDBC
Listed: Regulated Unofficial Market in Dusseldorf
EQS News ID: 1949233

 
End of Announcement EQS News Service

1949233  18-Jul-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1949233&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - Limes Schlosskliniken AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.